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Atherosclerosis, the underlying cause of the majority of cardiovascular diseases (CVDs), is a lipid-driven, inflam-
matory disease of the large arteries. Both innate and adaptive 
immune effector mechanisms operate during atherogenesis. In 
conjunction with hyperlipidemia, the interaction between the 
different immune cells and the secretion of immune regulatory 
and activating cytokines and chemokines determine the pro-
gression of atherosclerosis.1 The activation or dampening of the 
immune response is a delicate process that is tightly controlled 
by immune checkpoint proteins. This review will discuss the role 
of immune cell interactions in atherosclerosis and will highlight 
the current knowledge on how immune checkpoints are involved 
in this process. Furthermore, we will discuss clinical potential of 
immune checkpoint therapy for the treatment of atherosclerosis.
See Insight Into Esther Lutgens on page 1689
Immune Cell Interactions in Atherosclerosis
Atherosclerosis is initiated by the focal subendothelial accu-
mulation of apoB (apolipoprotein B) containing lipoproteins 
in the intimal layer of the arterial wall, which trigger both a 
monocytes-macrophages dominated innate immune response 
and an adaptive immune response.1–3
In brief, (ox)LDL ([oxidized] low-density lipoprotein) is the 
main driver of the atherosclerotic process. Oxidation of LDL gen-
erates oxidation-specific epitopes that are recognized as damage-
associated molecular patterns by pattern recognition receptors of 
the innate immune system, including scavenger receptors, Toll-
like receptors, soluble pattern recognition receptors, and natural 
antibodies secreted by B-1 cells, that all cause macrophage acti-
vation and release of proatherogenic cytokines.4
Binding and internalization of oxLDL particles by pattern 
recognition receptors primes antigen-presenting cells (APCs) 
to initiate T-cell responses. The most important APCs for the 
activation of naive T cells are dendritic cells (DCs), whereas 
DCs, macrophages, and B cells serve as APCs for differenti-
ated memory and effector T cells.5
After uptake of (ox)LDL, its apoB-derived peptides are pre-
sented on the APC cell surface in association with MHC (major 
histocompatibility complex) proteins.6 After binding of the anti-
gen-MHC complex to the T-cell receptor (TCR), naive T cells 
differentiate into various effector and regulatory subsets with 
distinct functions. Although not the most predominant cell type 
in the plaque, human and murine atherosclerotic lesions contain 
many T-cell subsets, including CD4+, FoxP3+, and CD8+ T cells.7,8
On engagement of antigen-MHCII with the TCR, naive 
CD4+ cells polarize into distinct subsets with characteristic 
cytokine profiles. T-helper 1 (Th1) cells which secrete proath-
erogenic cytokines such as IFN-γ (interferon γ) and TNF-α 
(tumor necrosis factor-α) are important drivers of atherosclero-
sis.1 Other Th cell subtypes present in atherosclerosis are Th2 
cells which secrete IL-4 (interleukin-4), IL-5, and IL-13, as well 
as Th17 cells with IL-17 and IL-22 as their signature cytokines. 
In contrast to the clear proatherogenic effects of Th1 cells, the 
impact of Th2 and Th17 cells in atherosclerosis is not clear.7 
Regulatory T cells, either derived from the thymus (natural 
Tregs [regulatory T cells]) or generated from naive CD4+ cells 
(induced Tregs) exert immunoregulation through a variety of 
Received on: February 21, 2018; final version accepted on: June 10, 2018.
From the Department of Surgery and Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands (E.R.); Department 
of Medical Biochemistry, Experimental Vascular Biology Laboratory, Academic Medical Center, Amsterdam, The Netherlands (E.L.); and Institute for 
Cardiovascular Prevention (IPEK), Ludwig Maximilian’s University (LMU), Munich, Germany (E.L.).
The online-only Data Supplement is available with this article at https://www.ahajournals.org/journal/atvb/doi/suppl/10.1161/atvbaha.118.307742.
Correspondence to Esther Lutgens, MD, PhD, Department of Medical Biochemistry, Experimental Vascular Biology Laboratory, Academic Medical 
Center (AMC), Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. E-mail E.Lutgens@amc.uva.nl
© 2018 American Heart Association, Inc.
Abstract—Innate and adaptive immune effector mechanisms, in conjunction with hyperlipidemia, are important drivers 
of atherosclerosis. The interaction between the different immune cells and the secretion of cytokines and chemokines 
determine the progression of atherosclerosis. The activation or dampening of the immune response is tightly controlled 
by immune checkpoints. Costimulatory and coinhibitory immune checkpoints represent potential targets for immune 
modulatory therapies for atherosclerosis. This review will discuss the current knowledge on immune checkpoints in 
atherosclerosis and the clinical potential of immune checkpoint targeted therapy for atherosclerosis.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38:1678-1688. 
DOI: 10.1161/ATVBAHA.118.307742.)
Key Words: atherosclerosis ◼ chemokines ◼ cytokines ◼ hyperlipidemia ◼ mice
2016 Jeffrey M. Hoeg Award Lecture
Immune Checkpoints in Atherosclerosis: Toward  
Immunotherapy for Atheroprotection
Ellen Rouwet, Esther Lutgens
Arterioscler Thromb Vasc Biol is available at https://www.ahajournals.org/journal/atvb DOI: 10.1161/ATVBAHA.118.307742
ATVB Named Lecture Review
Rouwet and Lutgens  Immune Checkpoint Proteins in Atherosclerosis  1679
mechanisms, including suppression of T-cell proliferation and 
production of anti-inflammatory cytokines, such as IL-10 and 
TGF-β (transforming growth factor-β).9 Tregs are especially 
present in early stages of atherosclerosis and decrease when 
lesions advance,10 and exert strong atheroprotective effects.
On engagement of antigen-MHCI with the TCR, naive 
CD8+ T cells differentiate into cytotoxic T cells, which have 
proatherogenic properties.11
Other lymphocyte subsets that promote atherosclerosis 
are CD4+CD28null T cells,12 natural killer T cells,13 and B2 
cells,14 whereas the role of TCRγδ+ T cells remains elusive.15,16 
Atheroprotective innate lymphocytes are innate lymphoid 
type II cells17,18 and B1 cells.14
Immune Checkpoints
The activation or dampening of the immune response is a deli-
cate process that is tightly controlled by immune checkpoint 
proteins. The family of immune checkpoint proteins, which 
mostly contains costimulatory and coinhibitory proteins of 
the B7 and TNF receptor families, was originally known to 
propagate or hamper T-cell proliferation and polarization 
after interaction between an APC and a T cell (signal 1). After 
recognition of its specific antigen via the TCR, signaling via 
costimulatory molecules induces T-cell activation (signal 2), 
which is further propagated via cytokines and chemokines 
(signal 3; Figure 1). Failure to costimulate results in T-cell 
anergy, where T cells proliferate, but do not fully mature and 
cannot mount a proper immune response, and can become 
tolerogenic.19 In contrast to the immune enhancing effects 
of costimulatory receptors and ligands, coinhibitory immune 
checkpoint receptor-ligand pairs dampen the activation of T 
cells and are required to maintain tolerance to self-antigens.20 
The coinhibitory receptors on the T-cell surface bind ligands 
expressed on APCs and subsequently generate inhibitory sig-
nals that block T-cell activation. Some immune checkpoints 
such as CD27, inducible costimulatory molecule (ICOS), and 
CD40 play a role in Treg development.21
We now know that immune checkpoint proteins are not 
only expressed on T cells and APCs but also on a variety 
of other immune cells, such as neutrophils, macrophages, 
and mast cells, as well as nonimmune cells, including plate-
lets, endothelial cells (ECs), vascular smooth muscle cells 
(VSMCs), adipocytes, hepatocytes, and epithelial cells. 
Immune checkpoints are also able to modulate inflammatory 
responses in these cell types.22
In the past decade, immune checkpoint modulation has 
yielded clinically successful cancer immunotherapy.23 Not 
unexpected, immune checkpoint proteins also play an important 
role in the pathogenesis of atherosclerosis by driving or inhibit-
ing multiple immunologic and inflammatory pathways in all 
stages of the disease.24–26 Stimulatory and inhibitory immune 
checkpoints thus represent potential targets for immune modu-
latory and anti-inflammatory therapies for atherosclerosis.
Immune Checkpoints in Atherosclerosis
Concepts on the role of immune checkpoint regulation in athero-
genesis are either inferred from hyperlipidemic mouse models, 
including LDL receptor-deficient (LDLR−/−) or apoE-deficient 
(ApoE−/−) mice, or—to a lesser extent—from observations in 
CVD patients or human atherosclerotic plaque specimens.
A plethora of immune checkpoints is involved in atherogen-
esis, each via their unique mechanisms as detailed below. The 
balance between the cell type or subset specific actions of these 
ligand-receptor pairs, for example, effector or regulatory T cell, 
macrophage, DC, or B cell within the network can determine 
whether the immune checkpoint protein promotes or limits ath-
erosclerosis. In Table I in the online-only Data Supplement, the 
function of the immune checkpoint proteins discussed below on 
atherosclerosis-relevant cell types is indicated in detail.
Costimulatory Immune Checkpoints
CD28-CD80/86
The best-characterized costimulatory dyad of the B7 family is 
CD28-CD80/86. CD28 is constitutively expressed on naive T 
cells and on B cells, thymocytes, and macrophages and induces 
costimulation via interaction with its ligands CD80 (B7-1) and 
CD86 (B7-2) on APCs. CD80 and CD86 are also considered 
markers of classically activated macrophages and are pres-
ent in human atherosclerotic plaques.27 Hyperlipidemic mice 
deficient in both CD80 and CD86 (CD80−/−CD86−/−LDLR−/− 
mice) on a high-fat diet developed less atherosclerosis and the 
effector T cells in their spleen and lymph nodes produced less 
IFN-γ, suggesting that the CD28-CD80/86 dyad regulates ath-
erosclerosis by priming T cells.28 Pharmacological inhibition 
of CD28-CD80/CD86 interactions by the CTLA-4 (cytotoxic 
T-lymphocyte–associated protein 4) immunoglobulin fusion 
protein abatacept reduced atherosclerosis in ApoE−/− mice.29 
Likewise, genetic deficiency of CD80 and CD86 as well as 
systemic treatment with abatacept prevented intimal thicken-
ing in a mouse model for postinterventional remodeling.30
Figure 1.  Antigen-presenting cell (APC)-T cell interactions in a nutshell. 
Signal 1: antigen presented by MHC (major histocompatibility complex) I 
(CD8 T cell) or MHCII (CD4 T cell) to the T-cell receptor (TCR) provides the 
first signal for T-cell activation. Signal 2: after activation by the TCR, T cells 
require secondary signaling via activating immune checkpoints (ie, costim-
ulatory molecules). Inhibitory immune checkpoints, that is, coinhibitory 
molecules, can also exert inhibitory actions. Signal 3: the last signal that 
propagates immune responses is provided by chemokines and cytokines.
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In line with this, human atherosclerotic plaques contained 
CD80/86+ macrophages, and CD28+ T cells, with higher 
expression levels of CD80 and CD86 in vulnerable compared 
with stable plaques.31 Furthermore, ex vivo blocking of CD80 
in human carotid endarterectomy specimens reduced cytokine 
secretion.32 Patients experiencing coronary artery disease and 
those at risk of stroke displayed an increased expression of 
CD80 and CD86 on monocyte-derived DCs and B cells.33,34 
CD80 was recently identified as an imaging marker to detect 
vulnerable plaques, both ex vivo in human atherosclerotic 
plaques and in vivo in atherosclerotic arteries of ApoE−/− 
mice.35,36 CD80-specific noninvasive imaging may thus be a 
promising tool to discriminate between stable and vulnerable 
atherosclerotic plaques and the CD28-CD80/86 dyad a poten-
tial therapeutic target for plaque stabilization.
ICOS-ICOSL
ICOS and its ligand ICOSL, members of the B7 family, have 
a dual role in atherosclerosis. LDLR−/− mice deficient in ICOS 
developed more atherosclerotic plaques containing more CD4+ 
T cells and macrophages. CD4+ T cells from ICOS-deficient 
mice proliferated more and secreted more proinflammatory 
cytokines, with a concomitant reduction in the number and 
suppressive function of Tregs. On the basis of these findings, it 
was suggested that ICOS modulates atherosclerosis through its 
effect on Treg responses.37 ICOS is also important for regulation 
of proatherogenic B-cell responses, a process that involves fol-
licular helper T cells, CD8+ Tregs, and ICOS-ICOSL signaling. 
Blocking ICOS-ICOSL signaling reduced the development of 
atherosclerosis in ApoE−/− mice by restoring control of the follic-
ular helper T-germinal center B-cell axis.38 The role of the ICOS-
ICOSL dyad in human atherosclerosis remains to be determined.
CD40-CD40L
CD40 ligand (CD40L, TNFSF5 [tumor necrosis factor super 
family 5], CD154) and its receptor CD40 (TNFRSF5 [tumor 
necrosis factor receptor super family 5]) is a well-character-
ized costimulatory ligand-receptor pair of the TNF(R) family 
that is involved in atherosclerosis.24,39,40 CD40L is primarily 
induced on T cells and platelets after activation, whereas its 
receptor CD40 is constitutively expressed by DCs, macro-
phages, B cells, and by other cell types such as ECs, VSMCs, 
platelets, and epithelial cells. This costimulatory dyad gener-
ates cell-appropriate inflammatory responses and upregulates 
other costimulatory molecules such as CD80/86. CD40-
CD40L interaction not only enhances T-cell stimulation and 
mediates T-cell help for cytotoxic T-cell priming but also 
induces B-cell activation and proliferation and is crucial for Ig 
isotype switching.41,42 Genetic or antibody-mediated disrup-
tion of CD40L in ApoE−/− mice and LDLR−/− mice decreased 
atherosclerotic plaque burden and induced collagen-rich 
plaques containing few immune cells, that is, the murine 
equivalent of a stable plaque.43–46 Likewise, inhibition of the 
CD40 receptor in ApoE−/− and LDLR−/− mice resulted in less 
atherosclerosis with a more stable plaque phenotype, which 
was attributed to hematopoietic CD40 inhibition.47 Moreover, 
deficiency of CD40L prevented the occurrence of angiotensin 
II–induced aneurysm formation.48
Although the CD40L expressing T cell is an important driver 
of atherosclerosis, the results of T-cell–specific deletion or over-
expression of CD40L are yet awaited. CD40L is also highly 
expressed on platelets, and platelet CD40L is also involved in 
the initiation and progression of atherosclerosis, independent 
of its role in platelet aggregation.49,50 CD40L-deficient platelets 
halted the platelet-induced aggravation of atherosclerosis by 
hampering platelet-leukocyte aggregation and leukocyte recruit-
ment to the endothelium.51 Similarly, ApoE−/− mice receiving 
CD40-deficient platelets displayed reduced atherosclerosis with 
less advanced plaques in a model of platelet-induced aggravated 
atherosclerosis.52 A recent study showed that activation of CD40 
in DCs indirectly attenuated atherosclerosis, by impairing lipid 
uptake resulting from inflammatory bowel disease.53 CD40 is 
also expressed by classically activated (M1) macrophages, and 
stimulation of CD40 on cultured monocytes and macrophages 
induced the release of proinflammatory mediators and matrix 
metalloproteinases.54 In contrast, CD40-deficient mice exhib-
ited reduced macrophage activation in atherosclerotic plaques.47 
Further roles for the CD40-CD40L dyad in the innate immune 
system remain to be elucidated.
In human atherosclerotic plaques, CD40 and CD40L are 
expressed on a wide variety of cell types, including T cells, 
DCs, B cells, ECs, and VSMCs.55 The expression of the 
CD40L-CD40 dyad was associated with features of plaque 
vulnerability. The soluble form of CD40L, sCD40L (soluble 
CD40 ligand), which is cleaved predominantly from plate-
lets after activation, is a useful biomarker for CVD severity. 
Elevated sCD40L levels are associated with hypercholesterol-
emia, stroke, diabetes mellitus, and acute coronary syndrome 
and can predict recurrent CVD.56–60
CD40-TRAF Signaling
CD40 has limited direct signaling capacity and needs TRAFs 
(TNF receptor–associated factors) to propel its signaling. 
CD40 has 2 distinct binding sites for TRAFs: a proximal site for 
TRAF6 and a distal site for TRAF1/2/3/5 binding, which enables 
CD40 to activate different signaling pathways.40 TRAF1 acts as 
a regulator rather than an activator of CD40 signaling. Multiple 
cell-type–specific CD40-TRAF signal transduction cascades are 
involved in atherosclerosis, including IKK/NFκB (inhibitor of 
kappa B kinase/nuclear factor kappa B), STAT3 (signal trans-
ducer and activation of transcription 3), PI3K/Akt (phosphati-
dyl inositol 3 kinase/Ak thymoma), p38/MAPK (phospo 38/
mitogen-activated protein kinase), ERK1/2 (extracellular signal-
regulated kinase 1/2), and JNK (c-Jun N-terminal kinase) path-
ways.40 CD40-TRAF signaling drives expression of cytokines, 
chemokines, adhesion molecules, other costimulatory molecules, 
matrix metalloproteinases, immunoglobulin class switching, and 
cell survival. The activation and functional consequences of a 
specific signaling cascade depend on the cell type involved. For 
example, in monocytes and macrophages, CD40-TRAF6 inter-
action, but not CD40-TRAF2/3/5, activated NFκB proinflam-
matory pathways, whereas CD40-TRAF2 signaling mediated 
activation of proinflammatory pathways in ECs and SMCs.61
In hyperlipidemic mice with site-directed mutagenesis 
at the CD40-TRAF6 or CD40-TRAF2/3/5 binding site in 
MHCII+ cells, CD40-TRAF6, but not CD40-TRAF2/3/5 sig-
naling, was proatherogenic.47,62 Mice lacking CD40-TRAF6 
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interactions exhibited impaired arterial leukocyte recruitment 
and hardly contained plaque macrophages. The majority of 
CD40-TRAF6−/− monocytes in blood and spleen were of the 
patrolling Ly6Clow subtype, and CD40-TRAF6−/− macrophages 
were anti-inflammatory.47 These data stress the importance of 
macrophage CD40-TRAF6 signaling in atherosclerosis.
OX40-OX40L
OX40 (TNFRSF4, CD134) is primarily expressed on activated 
CD4+ and CD8+ T cells, whereas its ligand OX40L (TNFSF4, 
CD252) is expressed by DCs, macrophages, ECs, mast cells, 
and B cells. OX40-OX40L interactions promote sustained T-cell 
responses by enhancing the survival and expansion of effector 
and memory T-cell populations as well as isotype switching of 
B cells. Interruption of the OX40-OX40L signaling pathway in 
C57Bl6 or LDLR−/− mice attenuated atherogenesis and induced 
regression of atherosclerotic lesions, in part by increasing the 
levels of protective anti-oxLDL IgM antibodies and lowering 
Th2 responses.63–65 Moreover, the less common allele of SNP 
rs3850641 of Ox40 was associated with myocardial infarction.65
Patients with an acute coronary syndrome had increased 
expression of OX40L in coronary plaques, increased expres-
sion of OX40 and OX40L in circulating T cells, and higher 
serum levels of soluble OX40L compared with those with 
stable angina.66,67 OX40L was also expressed by macrophages 
in carotid endarterectomy plaques.68
CD30-CD30L
CD30 (TNFRSF8) and its ligand CD30L (TNFSF8, CD153) 
are expressed on T and B cells. Interruption of CD30-CD30L 
signaling in LDLR−/− mice inhibited T-cell proliferation and 
activation and reduced atherosclerosis.69 Except for the iden-
tification of CD30+ macrophages and T cells in coronary 
plaques, the role of this costimulatory dyad in human athero-
sclerosis is unknown.70
CD137-CD137L
CD137 (TNFRSF9, 4-1BB) is expressed on activated CD4+ and 
CD8+ T cells, natural killer cells, monocytes, and DCs, whereas 
its ligand CD137L (TNFSF9, 4-1BBL) is expressed on mono-
cytes, macrophages, DCs, and activated B cells. Activation 
of CD137 increased T-cell infiltration and proinflammatory 
cytokine release in atherosclerotic lesions of hyperlipidemic 
mice and promoted leukocyte recruitment by inducing adhe-
sion molecule expression on ECs.71,72 Conversely, CD137 defi-
ciency was associated with reduced proinflammatory cytokine 
production and a reduction in atherosclerosis. CD137 signal-
ing also induced plaque instability with concurrent plaque 
necrosis, decreased collagen content, increased VSMC apop-
tosis, and increased macrophage and effector T-cell infiltra-
tion.73 CD137 is expressed in human atherosclerotic lesions on 
CD8+ T cells and ECs.71 Elevated plasma levels and monocyte-
associated expression of CD137 and CD137L were detected 
in patients with acute stroke or acute coronary syndrome.74,75
GITR-GITRL
GITR (glucocorticoid-induced TNFRSF18 [TNF receptor 
family related protein]) is highly expressed on Tregs but also 
on CD4+ effector memory T cells as well as on several other 
immune and nonimmune cells. GITR ligand (GITRL, TNFSF18) 
is expressed on ECs and APCs. In LDLR−/− mice, activation of 
GITR reduced atherosclerosis by limiting inflammation through 
increasing the number of Tregs in the vasculature and in lym-
phoid organs. These data suggested that the GITR-GITRL dyad 
is a costimulatory signal that limits atherosclerosis by enhancing 
Treg responses.76 In contrast, in human atherosclerosis, GITR 
and GITRL were mainly expressed on plaque macrophages, 
and GITR-GITRL interaction stimulated the production of the 
proinflammatory cytokine TNF-α and the matrix-degrading 
enzyme MMP-9 (matrix metalloproteinase-9).77 Thus, the exact 
role of the GITR-GITRL dyad is not clear yet.
CD27-CD70
CD27 (TNFRSF7) is found on naive T cells, B cells, and 
natural killer cells, whereas its ligand CD70 (TNFSF7) is 
expressed on activated T cells, B cells, macrophages, and DCs. 
CD27-CD70 interactions enhance the expansion of effector and 
memory T cells and are indispensable for Treg development. 
Deficiency of either CD70 or CD27 resulted in an impairment 
of Treg development in experimental models of atheroscle-
rosis. However, the mechanisms how CD70 and CD27 drive 
atherogenesis differed between the 2 models. CD70-deficient 
ApoE−/− mice displayed larger plaques with a more advanced 
plaque phenotype characterized by an increased necrotic core. 
Lack of CD70 impaired the inflammatory capacity and cho-
lesterol in- and efflux capacity of macrophages and rendered 
macrophages metabolically inactive and prone to apoptosis, 
resulting in increased necrotic core formation and progression 
of atherosclerosis. The amount of aortic Treg levels, as well as 
the total number of T cells and Tregs in the plaque were not 
affected, suggesting that although CD70-deficient mice have 
a reduction in Tregs, CD70 predominantly mediates its effects 
via macrophages.78 CD27-deficient ApoE−/− mice also showed 
exacerbated lesion development and increased inflammation, 
which was associated with a decrease in Tregs.79 Thymic Tregs 
of CD27−/−ApoE−/− mice were more prone to apoptosis, result-
ing in a decrease amount of Tregs in atherosclerotic plaques and 
the aorta. Consequently, CD27−/−ApoE−/− mice had increased 
aortic inflammation and more atherosclerosis.79 Patients with 
an acute myocardial infarction displayed a reduced expression 
of CD27 on circulating mononuclear cells.80 Conversely, CD70 
and CD27 expression were higher in ruptured than in stable 
human carotid artery plaques, most likely reflecting a compen-
satory immune regulatory response to plaque rupture.78,79
Herpes Virus Entry Mediator/LTbR-LIGHT
The costimulatory lymphotoxin-related inducible ligand 
LIGHT (TNF superfamily member 14 [TNFSF14]) and its 2 
receptors herpes virus entry mediator (TNFRSF14, HVEM 
[herpes virus entry mediator]) and lymphotoxin β-receptor 
(LTbR [lymphotoxin beta receptor], TNFRSF3) are expressed 
by a multitude of immune and nonimmune cells. LIGHT 
herpes virus entry mediator interaction promotes atherogen-
esis and plaque instability, by inducing proatherogenic cyto-
kines and matrix metalloproteinase activity.81 LTbR-deficient 
ApoE−/− mice exhibited lower plaque burden with reduced 
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plaque macrophage content and inflammation.82 Inhibition 
of LIGHT-LTbR interactions attenuated dyslipidemia in 
LDLR−/− mice.83 Patients with atherosclerosis displayed high 
plasma levels of LIGHT, associated with inflammation and 
lipid accumulation in macrophages.84,85–88 High expression 
levels of herpes virus entry mediator have been detected in 
human carotid plaques, mainly in relation to macrophages.81 




The coinhibitory receptor CTLA-4 (CD152) is primarily 
expressed on activated T cells and negatively regulates the 
CD80/86-CD28 pathway. Interaction of the ligands CD80 and 
CD86 on APCs with CTLA-4 limits effector T-cell activation 
and induces Treg responses, resulting in reduced inflamma-
tion. CTLA-4 is also constitutively expressed on Tregs and is 
required for exerting their suppressive functions. Moreover, 
Tregs require CTLA-4 to downregulate CD80/86 expression 
on APCs, thereby impairing antigen presentation and activa-
tion of immune responses.89
Overexpression of CTLA-4 by T cells in ApoE−/− mice 
reduced atherosclerotic lesion formation. This was associated 
with decreased numbers of effector T cells, decreased pro-
duction of proinflammatory cytokines, and decreased expres-
sion of the costimulatory molecules CD80 and CD86 on 
APCs.90 Conversely, antibody-mediated inhibition of CTLA-
4-CD80/86 interaction with CTLA-4 blocking antibodies in 
ApoE3Leiden mice resulted in a vast increase in atheroscle-
rosis.30 Interestingly, the CTLA-4-CD80/86 axis initiates the 
immune-suppressive tryptophan catabolism in DCs, result-
ing in increased expression of indoleamine-2,3-dioxygenase 
in DCs.91,92 In atherosclerosis, it could well be that CTLA-4 
mediates its protective effects partly via indoleamine-2,3-di-
oxygenase. Inhibition of indoleamine-2,3-dioxygenase has 
been shown to result in increased atherosclerosis by increas-
ing macrophage, VSMC activation, and EC activation.93 The 
role of the CTLA-4-CD80/86 inhibitory checkpoint in human 
atherosclerosis remains to be resolved.
PD-1-PD-L1/2
The other well-defined coinhibitory dyad is the PD-1 (pro-
grammed cell death 1, CD279) receptor which binds PD-L1 
(B7-H1, CD274) and PD-L2 (B7-DC, CD273). Both PD-1 
and PD-L1/2 are expressed on several cell types, including 
T cells, B cells, DCs, monocytes, and macrophages. Binding 
of PD-L1/2 to PD-1 inhibits T-cell activation. Deficiency of 
the ligands PD-L1 and PD-L2 increased the atherosclerotic 
burden in hypercholesterolemic LDLR−/− mice, which was 
associated with increased numbers of activated CD4+ T cells, 
higher serum levels of the proinflammatory cytokine TNF-α, 
and increased responsiveness of T cells to APCs.94 Similarly, 
LDLR−/− mice deficient in the receptor PD-1 or treated with a 
blocking anti-PD1 antibody displayed larger atherosclerotic 
lesions with more CD4+ and CD8+ T cells and macrophages, 
higher circulating TNF-α levels, and higher cytotoxic activ-
ity of CD8+ T cells.95 Although PD-1 deficiency was also 
associated with expansion of antiatherogenic Treg cells, pro-
atherogenic T-cell activation prevailed.96 These experimental 
findings indicate that the PD-1-PD-L1/2 pathway exerts an 
atheroprotective effect by suppressing APC-dependent T-cell 
activation. Patients with coronary atherosclerosis exhibited 
decreased expression of PD-1 and PD-L1 on circulating T 
cells and myeloid DCs.97 Furthermore, patients with an acute 
coronary syndrome had a lower expression of PD-L1 on 
peripheral blood Tregs when compared with those with stable 
coronary artery disease.98
TIGIT
Binding of the coinhibitory molecule TIGIT (T-cell immuno-
globulin and ITIM domain) with its ligands CD112, CD113, 
or CD155 inhibits T-cell proliferation and activation. In hyper-
cholesterolemic LDLR−/− mice, stimulation of TIGIT limited 
proatherogenic T cell responses, but did not affect atheroscle-
rotic lesion development.99
TIM Proteins
The TIM (T-cell immunoglobulin and mucin domain) pro-
teins are expressed by numerous immune cells, recognize 
apoptotic, phosphatidylserine expressing cells, and function 
both as costimulators and coinhibitors.100 TIM-1 exerts coin-
hibitory functions on Th2 cells, and was recently associated 
with carotid atherosclerosis in humans.87 Antibody-mediated 
blocking of TIM-1 in LDLR−/− mice resulted in enhanced 
Th2 responses and a decreased number of circulating Tregs, 
thereby aggravating atherosclerosis.101 Inhibition of TIM-3, a 
coinhibitor, but also an activator in innate immune responses 
increased the number of circulating monocytes and plaque 
macrophages as well as activated CD4+ T cells, while decreas-
ing Tregs, and increased atherosclerosis in LDLR−/− mice.102 
Inhibition of TIM-4, which is expressed as coinhibitor on 
DCs and immune modulator on marginal zone macrophages 
increased Th1 and Th2 responses, reduced the clearance of 
apoptotic cells and also promoted atherosclerosis in mice.101 
An SNP in TIMD4, the gene encoding for TIM-4 is associated 
with protection against CVD.103,104
LAG3
LAG3 (lymphocyte activation gene 3, CD223) is an inhibitory 
immune checkpoint protein that is in clinical development as 
an anticancer drug and considered very potent.105 Although 
mechanistic data on LAG3 on the development of atheroscle-
rosis are lacking, decreased LAG3 protein levels are associ-
ated with increased CVD risk, suggesting a role for LAG3 in 
atherosclerosis.106
Immunotherapy for Atherosclerosis
In spite of clinical and experimental data supporting a critical 
role for lipid-driven inflammation in atherosclerosis, pharma-
ceutical interventions to slow the progression of atheroscle-
rosis in patients thus far predominantly focused on reducing 
lipid levels. Only recently, the first trial that treated patients 
with coronary artery disease with an anti-inflammatory 
drug was published, the CANTOS trial (Canakinumab Anti-
inflammatory Thrombosis Outcome Study).107 In CANTOS, 
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patients with a history of myocardial infarction and an ele-
vated level of high-sensitivity C-reactive protein were ran-
domly assigned to a human monoclonal antibody targeting 
IL-1β, canakinumab, or to placebo. IL-1β inhibition reduced 
high-sensitivity C-reactive protein levels from baseline, when 
compared with placebo, and lowered the incidence of recur-
rent cardiovascular events. CANTOS is the first study in 
humans showing that anti-inflammatory therapy lowers the 
rate of cardiovascular events, independent of lipid levels.
Ongoing clinical trials on anti-inflammatory drugs in ath-
erosclerosis include the CIRT (Cardiovascular Inflammation 
Reduction Trial), which investigates whether inhibition of 
nonspecific T-cell inflammation with methotrexate will reduce 
further cardiovascular events in patients with coronary artery 
disease and diabetes mellitus or metabolic syndrome.108 The 
CANTOS study has helped moving the inflammatory hypoth-
esis of atherosclerosis forward. However, despite the benefi-
cial effects of IL-1β inhibition on cardiovascular outcomes, 
the incidence of fatal infection was almost 2-fold higher in 
the canakinumab than in the placebo group. This underlines 
the need to find other, better tailored anti-inflammatory agents 
that do not increase the risk of death from infection.107
On the basis of experimental data, inhibition of costimu-
latory molecules or stimulation of coinhibitory molecules are 
alternative anti-inflammatory interventions that might serve as 
targets for atheroprotection. A vast amount of knowledge on 
the role of immune checkpoint therapy is derived from cancer 
research because malignant neoplastic growth and metastasis 
require immunosuppression. Coinhibitory receptors are highly 
expressed in tumors and interactions with their ligands within 
the tumor microenvironment are crucial to the inhibition of anti-
tumor immune responses. In cancer immunotherapy, antibody-
mediated blockade of immune checkpoint inhibitors strongly 
promotes immune-mediated tumor destruction. Currently, 6 
immune checkpoint inhibitors are approved by the Food and 
Drug Administration for the treatment (of advanced stages) 
of several malignancies (https://www.fda.gov). Ipilimumab, 
an anti–CTLA-4 antibody, is approved for treatment of mela-
noma as well as renal cell carcinoma. Pembrolizumab and/or 
nivolumab, both anti-PD1 antibodies, are approved for treat-
ment of melanoma, nonsmall cell lung cancer, metastatic 
nonsquamous cell lung cancer, head and neck squamous cell 
carcinoma, refractory classical Hodgkin lymphoma, metastatic 
urothelial cell carcinoma, metastatic gastric and gastrointesti-
nal junction adenocarcinoma, renal cell carcinoma, and hepato-
cellular carcinoma. The 3 anti-PDL1 antibodies Atezolizumab, 
Avelumab, and Durvalumab are indicated for treatment of 
urothelial cell carcinoma, nonsmall cell lung cancer, and/or 
metastatic Merkel cell carcinoma. The list of FDA approved 
immune checkpoint inhibitors, as well as treatment indica-
tions, and therapy regimens, including combination therapy, is 
expected to grow exponentially during the next years.23,109
Although immune checkpoint inhibitors have substantially 
improved the clinical outcomes of numerous cancers, the release 
of restrained antitumor immune responses is associated with 
immune-related adverse events. The risk of immune-related 
adverse events for treatment with anti–CTLA-4, anti-PD1, or 
anti–PD-L1 antibodies is 70% to 90% and is even higher with 
combination regimens. The immune-related adverse events 
occur as a result of immune activation and consequent autoim-
mune-like diseases in different organ systems, including derma-
titis, colitis, hepatitis, pneumonitis, and endocrine disorders.110 
The adverse cardiovascular effects of these newly emerging tar-
geted anticancer drugs are unclear.111 The incidence of immune-
related cardiac toxicity is rare, with reported cardiac events in 
<1% patients, but is probably underreported, and will increase 
as the list of therapeutic indications for these agents keeps grow-
ing. Immune myocarditis and associated heart failure or conduc-
tion abnormalities are potentially fatal.112–114 In terms of vascular 
side effects, patients treated with anti–CTLA-4 antibodies have 
been reported to develop giant cell arteritis.115 Furthermore, 
inefficiency of the inhibitory PD-1-PD-L1 immune checkpoint 
was recently associated with inflammatory vessel disease.116 As 
long-term survival of cancer patients treated with checkpoint 
inhibitors becomes more common, chronic manifestation on 
atherosclerosis may become more evident.
In contrast to the paradigm shift in oncology where new 
therapeutic agents target immune cells rather than cancer 
cells, and the promising clinical benefits of manipulating T 
cell cosignaling to induce tolerance in the fields of rheumatoid 
arthritis and transplantation, immune checkpoint modulation 
for the treatment of CVD is still in its infancy.117,118 Although 
modulation of immune checkpoints has the potential to limit 
malignant and inflammatory diseases, the prominent role of 
these proteins in tumorigenesis, infection, autoimmunity, and 
atherosclerosis requires balanced and highly specific immuno-
modulation. Immune checkpoint therapy may induce off-tar-
get effects, of which immune suppression is the highest risk. 
However, short-term treatment with costimulatory antagonists 
or coinhibitory agonists on top of conventional therapy might 
be able to prevent atherosclerotic plaque rupture or reduce the 
increase inflammatory burden that is often seen after an acute 
cardiovascular event.1
As coinhibitory proteins are key in preventing autoim-
mune disease, combatting atherosclerosis, which shows fea-
tures of autoimmune disease, by coinhibitory agonists has 
potential beneficial effects. Experimental studies in hyperlip-
idemic mice have already proven a beneficial role for CTLA-4 
overexpression in limiting atherosclerotic disease,90 and ago-
nistic antibodies against the immune checkpoint TIM-1, a 
strong inducer of immune tolerance,100 would also have high 
potential to reduce atherosclerosis. However, data on the role 
of agonizing coinhibitory immune checkpoints in CVD are 
only limited, and additional studies, including monitoring of 
potential side effects such as tumorigenesis, and the potential 
of combination therapies, need to be performed.
As studies in hyperlipidemic mice have shown, blocking 
costimulation strongly reduces atherosclerosis. However, one 
of the risks of long-term treatment is immune suppression. 
To circumvent this problem, we have designed small mol-
ecule inhibitors that selectively block the interaction between 
CD40 and TRAF6 (TRAF-STOPs), without affecting CD40-
TRAF2/3/5 interactions, thereby keeping CD40-mediated 
immunity such as Ig-isotype switching and T-cell proliferation 
intact.119–121 Blocking CD40-TRAF6 interactions by small mol-
ecule inhibitor 6860766 or 6877002 reduced the accumulation 
of CD4+ and CD8+ T cells and macrophages in adipose tissue, 
decreased hepatosteatosis, and improved insulin sensitivity in 
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a mouse model of diet-induced obesity.119,122 Pharmacological 
inhibition of the CD40-TRAF6 pathway by compound 
6877002 reduced monocyte recruitment and macrophage acti-
vation in an experimental model of neuroinflammation.123 We 
recently demonstrated that TRAF-STOP treatment with either 
small molecule inhibitor 6860766 or small molecule inhibi-
tor 6877002 reduced early atherosclerosis development and 
halted the progression of established atherosclerosis in ApoE−/− 
mice.121 Moreover, TRAF-STOP treatment prevented classical 
monocyte activation, leukocyte recruitment and macrophage 
activation and migration in the arterial wall and induced a 
stable plaque phenotype (Figure 2). Nanomedicinal delivery 
of TRAF-STOPs specifically to macrophages, by incorporat-
ing compound 6877002 into rHDL (recombinant high-density 
lipoprotein) nanoparticles, reduced atherosclerotic plaque 
formation when given as prevention therapy, and reduced 
macrophage accumulation in existing plaques.122 Moreover, 
nanotherapeutic delivery of rHDL-6877002 was safe and had 
a favorable biodistribution in nonhuman primates.124
Conclusions
Advances in immunology have accelerated our understand-
ing of the complex immune network involved in the initia-
tion and progression of atherosclerosis. Immune checkpoint 
therapy is a powerful therapeutic strategy to treat atheroscle-
rosis. However, off-target effects might include immune sup-
pression and highly selective immune checkpoint modulation, 
such as blocking CD40-TRAF6 signaling in macrophages, or 
enhancing coinhibition is a promising new (nano)therapeutic 
strategy to prevent atherosclerotic events in high-risk patients 
on top of optimal treatment of conventional cardiovascular 
risk factors, while preserving immune defense mechanisms.
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Figure 2.  The costimulatory immune checkpoint proteins CD40L and CD40 are expressed on a plethora of cell types, that all exert their own CD40-signal 
transduction cascades. In monocytes and macrophages, CD40 signals via the adaptor molecule TRAF (TNF receptor–associated factor) 6. Inhibition of 
CD40-TRAF6 signaling via small molecule inhibitors directed against the CD40 binding grove at TRAF6 reduces canonical NFκB (nuclear factor kappa B) acti-
vation in myeloid cells, resulting in reduced myeloid cell recruitment and activation, thereby reducing atherosclerosis. As CD40-TRAF2/3/5 signaling remains 
intact, classical CD40-mediated immunity such as T-cell proliferation and immunoglobulin isotype switching are not affected. DC indicates dendritic cell; EC, 
dendritic cell; and SMC, smooth muscle cell.
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